Supernus Pharmaceuticals, Inc.
SUPN
$32.22
$0.872.78%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 5.99% | 14.17% | 24.17% | -6.58% | -1.80% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.99% | 14.17% | 24.17% | -6.58% | -1.80% |
| Cost of Revenue | 32.97% | -10.30% | -15.05% | -30.48% | -14.49% |
| Gross Profit | 2.33% | 17.74% | 31.39% | -2.28% | 0.22% |
| SG&A Expenses | 0.40% | -1.75% | -1.01% | 1.07% | 9.88% |
| Depreciation & Amortization | -13.41% | -8.26% | 0.00% | 0.86% | 1.79% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.38% | 0.79% | -1.48% | -1.56% | 7.33% |
| Operating Income | 3.01% | 268.77% | 208.44% | -220.37% | -40.53% |
| Income Before Tax | 2,564.85% | 354.47% | 253.57% | -97.31% | -97.18% |
| Income Tax Expenses | 6,075.14% | -75.08% | 139.19% | 101.50% | -101.92% |
| Earnings from Continuing Operations | 1,204.51% | 340.97% | 2,496.63% | -99.27% | -95.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1,204.51% | 340.97% | 2,496.63% | -99.27% | -95.39% |
| EBIT | 3.01% | 268.77% | 208.44% | -220.37% | -40.53% |
| EBITDA | -5.56% | 63.96% | 891.14% | -31.62% | -22.95% |
| EPS Basic | 1,185.58% | 338.55% | 2,482.89% | -99.26% | -95.44% |
| Normalized Basic EPS | 15.21% | 240.28% | 233.21% | -111.45% | -36.53% |
| EPS Diluted | 1,446.86% | 335.82% | 1,900.00% | -99.23% | -95.88% |
| Normalized Diluted EPS | 14.51% | 235.00% | 231.45% | -113.01% | -28.02% |
| Average Basic Shares Outstanding | 1.50% | 0.99% | 0.87% | 0.77% | 1.00% |
| Average Diluted Shares Outstanding | 2.10% | 2.58% | 2.24% | -10.93% | -10.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |